New York Life Investment Management’s IQ U.S. Mid Cap R&D Leaders ETF MRND Stock Holding History

New York Life Investment Management’s Portfolio MRND Stock Details MRND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-190,000	Closed	-$4.15M	–	1354
2023 Q3	$4.15M	Hold	190,000	–	–	0.04%	345
2023 Q2	$4.26M	Hold	190,000	–	–	0.04%	351
2023 Q1	$4.04M	Hold	190,000	–	–	0.04%	357
2022 Q4	$3.73M	Hold	190,000	–	–	0.04%	389
2022 Q3	$3.6M	Hold	190,000	–	–	0.04%	374
2022 Q2	$190K	Hold	190,000	–	–	﹤0.01%	1235
2022 Q1	$4.81M	Buy	+190,000	New	+$4.7M	0.25%	28

New York Life Investment Management's MRND Position: Q4 2023 in Review

New York Life Investment Management sold out of IQ U.S. Mid Cap R&D Leaders ETF (MRND) in Q4 2023, closing a stake of 190,000 shares — an estimated $4.15M sold.

New York Life Investment Management first reported a position in MRND in Q1 2022 and held it in 7 quarters. The position peaked at $4.81M in Q1 2022. 0 funds tracked by Wall St. Rank hold MRND as of Q4 2023.

New York Life Investment Management reported no remaining IQ U.S. Mid Cap R&D Leaders ETF position as of Q4 2023 after selling out during the quarter.
New York Life Investment Management sold 190,000 IQ U.S. Mid Cap R&D Leaders ETF shares in Q4 2023, an estimated $4.15M.
New York Life Investment Management first reported a position in IQ U.S. Mid Cap R&D Leaders ETF in Q1 2022 and held it in 7 quarters.
New York Life Investment Management's IQ U.S. Mid Cap R&D Leaders ETF position peaked at $4.81M in Q1 2022.
0 funds tracked by Wall St. Rank held IQ U.S. Mid Cap R&D Leaders ETF as of Q4 2023.

Based on New York Life Investment Management's 13F filing for Q4 2023, filed 6 Feb 2024.